Compare MMT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMT | ZURA |
|---|---|---|
| Founded | 1987 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.0M | 252.9M |
| IPO Year | N/A | N/A |
| Metric | MMT | ZURA |
|---|---|---|
| Price | $4.72 | $3.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 86.5K | ★ 398.3K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.04 | $0.97 |
| 52 Week High | $4.70 | $4.68 |
| Indicator | MMT | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 49.91 |
| Support Level | $4.67 | $3.66 |
| Resistance Level | $4.75 | $3.94 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 72.41 | 46.24 |
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, airlines, automotive, chemicals, electronics, and others.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.